Using AI to predict survival in glioma patients
MR Based Survival Prediction of Patients With Primary Glioma Ssing Deep Learning or Machine Learning
The First Affiliated Hospital of Zhengzhou University · NCT04215211
This study is trying to see if using artificial intelligence can help predict how long people with gliomas might live based on their unique tumor details and medical information.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 1 Year to 90 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Zhengzhou University (other) |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT04215211 on ClinicalTrials.gov |
What this trial studies
This observational registry collects clinical, molecular, and radiologic data from patients with primary gliomas to develop artificial intelligence algorithms for predicting survival outcomes. It focuses on integrating advanced MRI sequences and molecular pathology information to enhance the accuracy of survival predictions. By analyzing a large dataset of over 1000 patients, the study aims to provide personalized and non-invasive prognostic insights for glioma patients based on their specific tumor characteristics.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed diagnosis of primary glioma who are scheduled for tumor resection and have a life expectancy of more than three months.
Not a fit: Patients with non-glioma tumors, insufficient tumor tissue for molecular analysis, or those with severe systemic malfunctions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate survival predictions, allowing for better personalized treatment plans for glioma patients.
How similar studies have performed: Other studies utilizing AI for survival prediction in glioma patients have shown promising results, indicating the potential for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic devices * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfuctions
Where this trial is running
Zhengzhou, Henan
- Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (RECRUITING)
Study contacts
- Study coordinator: Zhenyu Zhang, Dr.
- Email: fcczhangzy1@zzu.edu.cn
- Phone: +86 17839973727
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioma, Prognosis, Radiomics, Deep Learning, Machine Learning